INHIBITION OF N6-METHYLADENOSINE (m6A) MODIFICATION AS A NOVEL TREATMENT STRATEGY FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL). (October 2022)